1. 2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. (20th October 2022) Authors: Coleman, Robert L; Oza, Amit M; Lorusso, Domenica; Aghajanian, Carol; Oaknin, Ana; Dean, Andrew; Colombo, Nicoletta; Weberpals, Johanne I; Clamp, Andrew R; Scambia, Giovanni; Leary, Alexandra; Holloway, Robert W; Gancedo, Margarita Amenedo; Fong, Peter C; Goh, Jeffrey C; O'Malley, David M; Goble,... Journal: International journal of gynecological cancer Issue: Volume 32(2022)Supplement 2 Page Start: A226 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Issue 10276 (27th February 2021) Authors: Hofman, Michael S; Emmett, Louise; Sandhu, Shahneen; Iravani, Amir; Joshua, Anthony M; Goh, Jeffrey C; Pattison, David A; Tan, Thean Hsiang; Kirkwood, Ian D; Ng, Siobhan; Francis, Roslyn J; Gedye, Craig; Rutherford, Natalie K; Weickhardt, Andrew; Scott, Andrew M; Lee, Sze-Ting; Kwan, Edmond M; Az... Journal: Lancet Issue: Volume 397:Issue 10276(2021) Page Start: 797 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA). Issue 8 (25th June 2020) Authors: Ngoi, Natalie YL; Heong, Valerie; Ow, Samuel; Chay, Wen Yee; Kim, Hee Seung; Choi, Chel Hun; Goss, Geraldine; Goh, Jeffrey C; Tai, Bee Choo; Lim, Diana GZ; Kaliaperumal, Nivashini; Au, Veonice B; Connolly, John E; Kim, Jae-Weon; Friedlander, Michael; Kim, Kidong; Tan, David SP Journal: International journal of gynecological cancer Issue: Volume 30:Issue 8(2020) Page Start: 1239 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A multicenter phase II randomized trial of durvalumab (MEDI‐4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA). Issue 8 (August 2020) Authors: Ngoi, Natalie YL; Heong, Valerie; Ow, Samuel; Chay, Wen Yee; Kim, Hee Seung; Choi, Chel Hun; Goss, Geraldine; Goh, Jeffrey C; Tai, Bee Choo; Lim, Diana GZ; Kaliaperumal, Nivashini; Au, Veonice B; Connolly, John E; Kim, Jae‐Weon; Friedlander, Michael; Kim, Kidong; Tan, David SP Journal: International journal of gynecological cancer Issue: Volume 30:Issue 8(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Issue 10379 (11th March 2023) Authors: Motzer, Robert J; Russo, Paul; Grünwald, Viktor; Tomita, Yoshihiko; Zurawski, Bogdan; Parikh, Omi; Buti, Sebastiano; Barthélémy, Philippe; Goh, Jeffrey C; Ye, Dingwei; Lingua, Alejo; Lattouf, Jean-Baptiste; Albigès, Laurence; George, Saby; Shuch, Brian; Sosman, Jeffrey; Staehler, Michael; Vázquez... Journal: Lancet Issue: Volume 401:Issue 10379(2023) Page Start: 821 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Issue 5 (May 2020) Authors: Pfisterer, Jacobus; Shannon, Catherine M; Baumann, Klaus; Rau, Joern; Harter, Philipp; Joly, Florence; Sehouli, Jalid; Canzler, Ulrich; Schmalfeldt, Barbara; Dean, Andrew P; Hein, Alexander; Zeimet, Alain G; Hanker, Lars C; Petit, Thierry; Marmé, Frederik; El-Balat, Ahmed; Glasspool, Rosalind; de... Journal: Lancet oncology Issue: Volume 21:Issue 5(2020) Page Start: 699 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Issue 5 (May 2020) Authors: Pfisterer, Jacobus; Shannon, Catherine M; Baumann, Klaus; Rau, Joern; Harter, Philipp; Joly, Florence; Sehouli, Jalid; Canzler, Ulrich; Schmalfeldt, Barbara; Dean, Andrew P; Hein, Alexander; Zeimet, Alain G; Hanker, Lars C; Petit, Thierry; Marmé, Frederik; El-Balat, Ahmed; Glasspool, Rosalind; de... Journal: Lancet oncology Issue: Volume 21:Issue 5(2020) Page Start: 699 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Issue 6 (June 2022) Authors: Motzer, Robert; Porta, Camillo; Alekseev, Boris; Rha, Sun Young; Choueiri, Toni K; Mendez-Vidal, Maria Jose; Hong, Sung-Hoo; Kapoor, Anil; Goh, Jeffrey C; Eto, Masatoshi; Bennett, Lee; Wang, Jinyi; Pan, Jie Janice; Saretsky, Todd L; Perini, Rodolfo F; He, Cixin Steven; Mody, Kalgi; Cella, David Journal: Lancet oncology Issue: Volume 23:Issue 6(2022) Page Start: 768 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Issue 3 (March 2023) Authors: Choueiri, Toni K; Eto, Masatoshi; Motzer, Robert; De Giorgi, Ugo; Buchler, Tomas; Basappa, Naveen S; Méndez-Vidal, María José; Tjulandin, Sergei; Hoon Park, Se; Melichar, Bohuslav; Hutson, Thomas; Alemany, Carlos; McGregor, Bradley; Powles, Thomas; Grünwald, Viktor; Alekseev, Boris; Rha, Sun Youn... Journal: Lancet oncology Issue: Volume 24:Issue 3(2023) Page Start: 228 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial. Issue 8 (17th August 2022) Authors: Fizazi, Karim; Retz, Margitta; Petrylak, Daniel P; Goh, Jeffrey C; Perez-Gracia, Jose; Lacombe, Louis; Zschäbitz, Stefanie; Burotto, Mauricio; Mahammedi, Hakim; Gravis, Gwenaelle; Bastos, Diogo Assed; McCune, Steven L; Vázquez Limón, Juan Carlos; Kwan, Edmond M; Castellano, Daniel; Fléchon, Aude;... Journal: Journal for immunotherapy of cancer Issue: Volume 10:Issue 8(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗